Bleeding Disorders
From the Journals
Novel point-of-care assay appears accurate in monitoring hemophilia A
The ClotChip assay may be an appropriate tool for “real-world” decision making around the use of coagulation factor replacement therapy in...
Conference Coverage
Subcutaneous marstacimab appears safe in hemophilia A and B
MELBOURNE – Subcutaneous marstacimab produced significant reductions in bleeding rates in hemophilia A and B with reasonable safety and...
Conference Coverage
Consider bleeding risk with oral anticoagulants in patients with GI cancer
MELBOURNE – Patients with some GI cancers may be at increased risk of bleeding, which can complicate the choice of antithrombotic therapies.
From the Journals
rFVIII product shows better PK profile than rFVIIIFc
In a pharmacokinetic crossover study of 18 patients with severe hemophilia A, the median time to achieve factor VIII threshold levels (1 IU/dL)...
News
FDA expands Doptelet approval to ITP patients with thrombocytopenia
The drug is now indicated for treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) with insufficient response to...
Latest News
Day 75 is key threshold in FVIII inhibitor development
For previously untreated patients with severe hemophilia A, the risk for developing factor VIII inhibitors is near zero after 75 exposure days.
Conference Coverage
Rozanolixizumab may offer new treatment paradigm for ITP
AMSTERDAM – “Data from this study indicate that we can achieve effective increases in platelet levels, we can observe decreasing IgG levels, and...
Conference Coverage
Platelet glycoprotein genotypes predict responses to ITP therapy
AMSTERDAM – The use of genotyping could help clinicians rule out the use of splenectomy for certain patients who would be unlikely to benefit.
From the Journals
Real-world data confirm nonacog alfa efficacy in hemophilia B
A postmarketing study in Japan shows high rates of effectiveness for both routine prophylaxis and on-demand treatment with the recombinant factor...
Conference Coverage
Rivaroxaban tied to higher GI bleeding than other NOACs
SAN DIEGO – Real-world studies comparing the GI bleeding rates among different non–vitamin K anticoagulants have been limited.
From the Journals
Need for VWF concentrate therapy appears low
The need for treatment with VWF concentrate appeared low in the study cohort, with the exception of patients with severe disease.